Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axi-cel consolidation in high-risk LBCL
NCT06609304Phase 4Recruiting
- Sponsor
- Zhengzhou University
- Start
- Sep 2024
- Primary completion
- Aug 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 4 trial of axicabtagene ciloleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Zhengzhou University. Started Sep 2024; status: recruiting.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06609304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06609304.